Highly Selective Butyrylcholinesterase Inhibitors With Tunable Duration of Action by Chemical Modification of Transferable Carbamate Units Exhibit Pronounced Neuroprotective Effect in an Alzheimer’s Disease Mouse Model

A new and rapid colorimetric determination of acetylcholinesterase activity

Ellman, G. L., Courtney, K. D., Andres, V., & Featherstone, R. M. (1961) · Biochemical Pharmacology · doi:10.1016/0006-2952(61)90145-9 · Cited by 27,221 · see citing works

Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen

Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0897 · Cited by 6,763 · see citing works

The cholinergic hypothesis of geriatric memory dysfunction

Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545 · see citing works

SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE

DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565 · see citing works

Oxidative stress hypothesis in Alzheimer’s disease

Markesbery, W. R. (1997) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(96)00629-6 · Cited by 2,383 · see citing works

Structures of Human Acetylcholinesterase in Complex with Pharmacologically Important Ligands

Cheung, J., Rudolph, M. J., Burshteyn, F., Cassidy, M. S., Gary, E. N., Love, J. D., Franklin, M. C., & Height, J. J. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300871x · Cited by 1,377 · see citing works

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224 · see citing works

Oxidative stress and Alzheimer disease

Christen, Y. (2000) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.2.621s · Cited by 1,158 · see citing works

A colorimetric method for determining low concentrations of mercaptans

Ellman, G. L. (1958) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(58)90014-6 · Cited by 1,085 · see citing works

Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress

Murphy, T. H., Miyamoto, M., Sastre, A., Schnaar, R. L., & COYLE, J. T. (1989) · Neuron · doi:10.1016/0896-6273(89)90043-3 · Cited by 1,033 · see citing works

The amyloid hypothesis for Alzheimer’s disease: A critical reappraisal

Hardy, J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06181.x · Cited by 814 · see citing works

Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline

Raina, P., Santaguida, P., Ismaila, A., Patterson, C., Cowan, D., Levine, M., Booker, L., & Oremus, M. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-5-200803040-00009 · Cited by 771 · see citing works

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753 · see citing works

Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent

Greig, N. H., Utsuki, T., Ingram, D. K., Wang, Y., Pepeu, G., Scali, C., Yu, Q.-S., Mamczarz, J., Holloway, H. W., Giordano, T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508575102 · Cited by 745 · see citing works

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD

Winblad, B. G., Engedal, K., Soininen, H. S., Verhey, F. R. J., Waldemar, G., Wimo, A. B., Wetterholm, A.-L., Zhang, R., Haglund, A., Subbiah, P., et al. (2001) · Neurology · doi:10.1212/wnl.57.3.489 · Cited by 721 · see citing works

Clinical trials and late‐stage drug development for <scp>A</scp>lzheimer's disease: an appraisal from 1984 to 2014

Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651 · see citing works

Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease&lt;subtitle&gt;A Randomized Controlled Trial&lt;/subtitle&gt;

Green, R. C. (2009) · JAMA · doi:10.1001/jama.2009.1866 · Cited by 643 · see citing works

Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction

Maurice, T., Lockhart, B. P., & Privat, A. (1996) · Brain Research · doi:10.1016/0006-8993(95)01032-7 · Cited by 524 · see citing works

Revisiting the cholinergic hypothesis in the development of Alzheimer's disease

Craig, L. A., Hong, N. S., & McDonald, R. J. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.03.001 · Cited by 487 · see citing works

Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses.

Lockridge, O. (2015) · Pharmacology and Therapeutics · doi:10.1016/j.pharmthera.2014.11.011 · Cited by 399 · see citing works

Oxidative Stress Induces a Form of Programmed Cell Death with Characteristics of Both Apoptosis and Necrosis in Neuronal Cells

Tan, S., Wood, M. R., & Maher, P. A. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71010095.x · Cited by 337 · see citing works

Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease

Li, Q., Yang, H., Chen, Y., & Sun, H. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.03.062 · Cited by 331 · see citing works

Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer’s disease resemble embryonic development—A study of molecular forms

Arendt, T., Brückner, M. K., Lange, M., & Bigl, V. (1992) · Neurochemistry International · doi:10.1016/0197-0186(92)90189-x · Cited by 314 · see citing works

Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine

Zemek, F., Drtinová, L., Nepovimová, E., Šepsová, V., Korábečný, J., Klimeš, J., & Kuča, K. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.914168 · Cited by 307 · see citing works

Comparison of the Binding of Reversible Inhibitors to Human Butyrylcholinesterase and Acetylcholinesterase: A Crystallographic, Kinetic and Calorimetric Study

Rosenberry, T. L., Brazzolotto, X., Macdonald, I. R., Wandhammer, M., Trovaslet-Leroy, M., Darvesh, S., & Nachon, F. (2017) · Molecules · doi:10.3390/molecules22122098 · Cited by 305 · see citing works

DSX: A Knowledge-Based Scoring Function for the Assessment of Protein–Ligand Complexes

Neudert, G., & Klebe, G. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci200274q · Cited by 264 · see citing works

Differences in Active Site Gorge Dimensions of Cholinesterases Revealed by Binding of Inhibitors to Human Butyrylcholinesterase

Saxena, A., Redman, A. M. G., Jiang, X., Lockridge, O., & Doctor, B. P. (1997) · Biochemistry · doi:10.1021/bi971425+ · Cited by 251 · see citing works

Mechanism of glutamate-induced neurotoxicity in HT22 mouse hippocampal cells

Fukui, M., Song, J., Choi, J.-Y., Choi, H. J., & Zhu, B. T. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.06.059 · Cited by 237 · see citing works

pKaValues of Some Piperazines at (298, 303, 313, and 323) K

Khalili, F., Henni, A., & East, A. L. L. (2009) · Journal of Chemical & Engineering Data · doi:10.1021/je900005c · Cited by 219 · see citing works

Alzheimer´s Disease and Oxidative Stress: A Review

Pohanka, M. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113206660258 · Cited by 219 · see citing works

Synthesis of Novel Phenserine-Based-Selective Inhibitors of Butyrylcholinesterase for Alzheimer's Disease

Yu, Q., Holloway, H. W., Utsuki, T., Brossi, A. R., & Greig, N. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980459s · Cited by 213 · see citing works

Donepezil treatment of patients with MCI

Doody, R. S., Ferris, S. H., Salloway, S., Sun, Y., Goldman, R. S., Watkins, W. E., Xu, Y., & Murthy, A. K. (2009) · Neurology · doi:10.1212/01.wnl.0000344650.95823.03 · Cited by 212 · see citing works

Rivastigmine

Spencer, C. M., & Noble, S. (1998) · Drugs & Aging · doi:10.2165/00002512-199813050-00005 · Cited by 187 · see citing works

Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease

Rountree, S. D., Chan, W., Pavlik, V. N., Darby, E. J., Siddiqui, S., & Doody, R. S. (2009) · Alzheimers Res Ther · doi:10.1186/alzrt7 · Cited by 181 · see citing works

Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer’s disease

Rao, A. A., Sridhar, G. R., & Das, U. N. (2007) · Medical Hypotheses · doi:10.1016/j.mehy.2007.03.032 · Cited by 180 · see citing works

Development of an in-vivo active reversible butyrylcholinesterase inhibitor

Košak, U., Brus, B., Knez, D., Šink, R., Žakelj, S., Trontelj, J., Pišlar, A. H., Šlenc, J., Gobec, M., Živin, M., et al. (2016) · Scientific Reports · doi:10.1038/srep39495 · Cited by 176 · see citing works

PART, a distinct tauopathy, different from classical sporadic Alzheimer disease.

Jellinger, K. A., Alafuzoff, I., Attems, J., Beach, T. G., Cairns, N. J., Crary, J. F., Dickson, D. W., Hof, P. R., Hyman, B. T., Jack, C. R., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1407-2 · Cited by 171 · see citing works

Comparison of Consensus Scoring Strategies for Evaluating Computational Models of Protein−Ligand Complexes

Oda, A., Tsuchida, K., Takakura, T., Yamaotsu, N., & Hirono, S. (2005) · Journal of Chemical Information and Modeling · doi:10.1021/ci050283k · Cited by 167 · see citing works

Blockade of Tau Hyperphosphorylation and Aβ1–42 Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic and σ1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer’s Disease

Lahmy, V., Meunier, J., Malmström, S., Naert, G., Givalois, L., Kim, S. H., Villard, V., Vamvakides, A., & Maurice, T. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.70 · Cited by 163 · see citing works

Donepezil–tacrine hybrid related derivatives as new dual binding site inhibitors of AChE

Alonso, D. A., Dorronsoro, I., Rubio, L., Muñoz, P., García‐Palomero, E., del Monte, M., Bidon‐Chanal, A., Orozco, M., Luque, F. J., Castro, A., et al. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.09.029 · Cited by 157 · see citing works

Carbamates with Differential Mechanism of Inhibition Toward Acetylcholinesterase and Butyrylcholinesterase

Darvesh, S., Darvesh, K. V., McDonald, R. S., Mataija, D., Walsh, R., Mothana, S., Lockridge, O., & Martin, E. V. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8002075 · Cited by 154 · see citing works

Design, Synthesis, and Biological Evaluation of Conformationally Restricted Rivastigmine Analogues

Bolognesi, M. L., Bartolini, M., Cavalli, A., Andrisano, V., Rosini, M., Minarini, A., & Melchiorre, C. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049782n · Cited by 150 · see citing works

Specific Targeting of Acetylcholinesterase and Butyrylcholinesterase Recognition Sites. Rational Design of Novel, Selective, and Highly Potent Cholinesterase Inhibitors

Savini, L., Gaeta, A., Fattorusso, C., Catalanotti, B., Campiani, G., Chiasserini, L., Pellerano, C., Novellino, E., McKissic, D., & Saxena, A. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0255668 · Cited by 148 · see citing works

Catalytic Reaction Mechanism of Acetylcholinesterase Determined by Born−Oppenheimer Ab Initio QM/MM Molecular Dynamics Simulations

Zhou, Y., Wang, S., & Zhang, Y. (2010) · The Journal of Physical Chemistry B · doi:10.1021/jp104258d · Cited by 141 · see citing works

Expression of recombinant acetylcholinesterase in a baculovirus system: kinetic properties of glutamate 199 mutants

Radić, Z., Gibney, G., Kawamoto, S., MacPhee-Quigley, K., Bongiorno, C., & Taylor, P. (1992) · Biochemistry · doi:10.1021/bi00155a032 · Cited by 133 · see citing works

Asp70 in the Peripheral Anionic Site of Human Butyrylcholinesterase

Masson, P., Froment, M.-T., Bartels, C. F., et al. (1996) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1996.00036.x · Cited by 132 · see citing works

Alzhemed: A Potential Treatment for Alzheimers Disease

Aisen, P. S. S., Gauthier, S. G., Vellas, B. J., Briand, R., Saumier, D., Laurin, J., & Garceau, D. (2007) · Current Alzheimer Research · doi:10.2174/156720507781788882 · Cited by 115 · see citing works

Discovery of Highly Selective and Nanomolar Carbamate-Based Butyrylcholinesterase Inhibitors by Rational Investigation into Their Inhibition Mode

Sawatzky, E., Wehle, S., Kling, B., Wendrich, J., Bringmann, G., Sotriffer, C., Heilmann, J., & Decker, M. W. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01674 · Cited by 103 · see citing works

Homobivalent Quinazolinimines as Novel Nanomolar Inhibitors of Cholinesterases with Dirigible Selectivity toward Butyrylcholinesterase

Decker, M. W. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060682m · Cited by 101 · see citing works

Tryptophan-derived butyrylcholinesterase inhibitors as promising leads against Alzheimer's disease

Meden, A., Knez, D., Jukič, M., et al. (2019) · Chemical Communications · doi:10.1039/c9cc01330j · Cited by 101 · see citing works

Are cases with tau pathology occurring in the absence of Aβ deposits part of the AD-related pathological process?

Braak, H., & Tredici, K. D. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1356-1 · Cited by 99 · see citing works

“Back Door” Opening Implied by the Crystal Structure of a Carbamoylated Acetylcholinesterase

Bartolucci, C., Perola, E., Cellai, L., et al. (1999) · Biochemistry · doi:10.1021/bi982723p · Cited by 97 · see citing works

Neuroprotective Tri- and Tetracyclic BChE Inhibitors Releasing Reversible Inhibitors upon Carbamate Transfer

Darras, F. H., Kling, B., Heilmann, J., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml3001825 · Cited by 97 · see citing works

Possible biochemical basis of memory disorder in Alzheimer disease

Smith, C. M., & Swash, M. (1978) · Annals of Neurology · doi:10.1002/ana.410030602 · Cited by 88 · see citing works

Inhibition of acetylcholinesterase by two genistein derivatives: kinetic analysis, molecular docking and molecular dynamics simulation

Fang, J., Wu, P., Yang, R., Gao, L., Li, C., Wang, D., Wu, S., Liu, A., & Du, G. (2014) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2014.10.002 · Cited by 87 · see citing works

Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer’s Disease Agents

Montanari, S., Scalvini, L., Bartolini, M., Belluti, F., Gobbi, S., Andrisano, V., Ligresti, A., Marzo, V. D., Rivara, S., Mor, M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00609 · Cited by 87 · see citing works

Molecular Recognition by Cholesterol Esterase of Active Site Ligands: Structure−Reactivity Effects for Inhibition by Aryl Carbamates and Subsequent Carbamylenzyme Turnover

Feaster, S. R., Lee, K., Baker, N., Hui, D. Y., & Quinn, D. M. (1996) · Biochemistry · doi:10.1021/bi961677v · Cited by 81 · see citing works

Aromatic amino‐acid residues at the active and peripheral anionic sites control the binding of E2020 (Aricept®) to cholinesterases

Saxena, A., Fedorko, J. M., Vinayaka, C. R., et al. (2003) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03837.x · Cited by 80 · see citing works

Synthesis, Biological Evaluation, and Computational Studies of Tri- and Tetracyclic Nitrogen-Bridgehead Compounds as Potent Dual-Acting AChE Inhibitors andhH3Receptor Antagonists

Darras, F. H., Pockes, S., Huang, G., Wehle, S., Straßer, A., Wittmann, H., Nimczick, M., Sotriffer, C., & Decker, M. W. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn4002126 · Cited by 80 · see citing works

Amine basicities in benzene and in water

Frenna, V., Vivona, N., Consiglio, G., et al. (1985) · Journal of the Chemical Society Perkin Transactions 2 · doi:10.1039/p29850001865 · Cited by 80 · see citing works

Inhibition of Human Acetyl- and Butyrylcholinesterase by Novel Carbamates of (−)- and (+)-Tetrahydrofurobenzofuran and Methanobenzodioxepine

Luo, W., Yu, Q., Kulkarni, S. S., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050578p · Cited by 79 · see citing works

Probing the Peripheral Site of Human Butyrylcholinesterase

Macdonald, I. R., Martin, E. V., Rosenberry, T. L., et al. (2012) · Biochemistry · doi:10.1021/bi300955k · Cited by 74 · see citing works

Learning performances and vulnerability to amyloid toxicity in the butyrylcholinesterase knockout mouse

Maurice, T., Strehaïano, M., Siméon, N., Bertrand‐Gaday, C., & Chatonnet, A. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.08.026 · Cited by 73 · see citing works

Identification of a neuroprotective and selective butyrylcholinesterase inhibitor derived from the natural alkaloid evodiamine

Huang, G., Kling, B., Darras, F. H., Heilmann, J., & Decker, M. W. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.05.002 · Cited by 72 · see citing works

Isosorbide-2-benzyl Carbamate-5-salicylate, A Peripheral Anionic Site Binding Subnanomolar Selective Butyrylcholinesterase Inhibitor

Carolan, C. G., Dillon, G. P., Khan, D., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm9014845 · Cited by 69 · see citing works

Acetylcholinesterase Inhibitors: SAR and Kinetic Studies on ω-[N-Methyl-N-(3-alkylcarbamoyloxyphenyl)methyl]aminoalkoxyaryl Derivatives

Rampa, A., Piazzi, L., Belluti, F., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010914b · Cited by 67 · see citing works

Structure–Activity Relationships and Computational Investigations into the Development of Potent and Balanced Dual-Acting Butyrylcholinesterase Inhibitors and Human Cannabinoid Receptor 2 Ligands with Pro-Cognitive in Vivo Profiles

Dolles, D., Hoffmann, M., Gunesch, S., Marinelli, O., Möller, J., Santoni, G., Chatonnet, A., Lohse, M. J., Wittmann, H.-J., Strasser, A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01760 · Cited by 67 · see citing works

Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Aβ1–42 aggregation for Alzheimer’s disease therapeutics

Kwon, Y. E., Park, J. Y., No, K. T., Shin, J. H., Lee, S. K., Eun, J. S., Yang, J. H., Shin, T. Y., Kim, D. K., Chae, B. S., et al. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.07.003 · Cited by 64 · see citing works

Pure human butyrylcholinesterase hydrolyzes octanoyl ghrelin to desacyl ghrelin.

Schopfer, L., Lockridge, O., & Brimijoin, S. (2015) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2015.05.017 · Cited by 61 · see citing works

Long chain analogs of physostigmine as potential drugs for Alzheimer's disease: new insights into the mechanism of action in the inhibition of acetylcholinesterase

Perola, E., Cellai, L., Lamba, D., Filocamo, L., & Brufani, M. (1997) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(97)00133-7 · Cited by 60 · see citing works

Increased Expression of Readthrough Acetylcholinesterase Variants in the Brains of Alzheimer’s Disease Patients

Campanari, M., Navarrete, F., Ginsberg, S. D., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160220 · Cited by 47 · see citing works

The First Dual ChE/FAAH Inhibitors: New Perspectives for Alzheimer's Disease?

Rampa, A., Bartolini, M., Bisi, A., Belluti, F., Gobbi, S., Andrisano, V., Ligresti, A., & Marzo, V. D. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml200313p · Cited by 46 · see citing works

Selective inhibition of human acetylcholinesterase by xanthine derivatives: In vitro inhibition and molecular modeling investigations

Mohamed, T., Osman, W., Tin, G., & Rao, P. P. N. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.05.092 · Cited by 45 · see citing works

NORADRENERGIC AND CHOLINERGIC SYSTEMS IN SENILE DEMENTIA OF ALZHEIMER TYPE

Perry, E., Tomlinson, B. E., Blessed, G., Perry, R., Cross, A. J., & Tj, C. (1981) · The Lancet · doi:10.1016/s0140-6736(81)90327-5 · Cited by 43 · see citing works

Aspirin Hydrolysis in Plasma Is a Variable Function of Butyrylcholinesterase and Platelet-activating Factor Acetylhydrolase 1b2 (PAFAH1b2)

Zhou, G., Marathe, G. K., Hartiala, J., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.427674 · Cited by 42 · see citing works

Kinetics of Torpedo californica acetylcholinesterase inhibition by bisnorcymserine and crystal structure of the complex with its leaving group

Bartolucci, C., Stojan, J., Yu, Q., Greig, N. H., & Lamba, D. (2012) · Biochemical Journal · doi:10.1042/bj20111675 · Cited by 31 · see citing works

On the Influence of the Protonation States of Active Site Residues on AChE Reactivation: A QM/MM Approach

Driant, T., Nachon, F., Ollivier, C., et al. (2017) · ChemBioChem · doi:10.1002/cbic.201600646 · Cited by 31 · see citing works

Hexahydrochromeno[4,3-b]pyrrole Derivatives as Acetylcholinesterase Inhibitors

Bolognesi, M. L., Andrisano, V., Bartolini, M., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm000991r · Cited by 30 · see citing works

Experimental and theoretical investigations into the stability of cyclic aminals

Sawatzky, E., Drakopoulos, A., Rölz, M., et al. (2016) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.12.221 · Cited by 28 · see citing works

A Novel Way To Radiolabel Human Butyrylcholinesterase for Positron Emission Tomography through Irreversible Transfer of the Radiolabeled Moiety

Sawatzky, E., Al‐Momani, E., Kobayashi, R., Higuchi, T., Samnick, S., & Decker, M. W. (2016) · ChemMedChem · doi:10.1002/cmdc.201600223 · Cited by 25 · see citing works

Design, synthesis and evaluation of carbamate-modified (−)-N1-phenethylnorphysostigmine derivatives as selective butyrylcholinesterase inhibitors

TAKAHASHI, J. C., Hijikuro, I., Kihara, T., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.01.035 · Cited by 21 · see citing works

Synthesis, Biological Evaluation and Molecular Docking Study of Hydrazone-Containing Pyridinium Salts as Cholinesterase Inhibitors

Parlar, S., Bayraktar, G., Tarikogullari, A. H., et al. (2016) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c16-00221 · Cited by 21 · see citing works

Investigation into selective debenzylation and ring cleavage of quinazoline based heterocycles

Sawatzky, E., Bukowczan, J., & Decker, M. W. (2014) · Tetrahedron Letters · doi:10.1016/j.tetlet.2014.03.109 · Cited by 12 · see citing works

Unexpected protonation state of Glu197 discovered from simulations of tacrine in butyrylcholinesterase

Wan, X., Yao, Y., Fang, L., & Liu, J. (2018) · Physical Chemistry Chemical Physics · doi:10.1039/c8cp01566j · Cited by 11 · see citing works

Memantine Derivatives as Multitarget Agents in Alzheimer’s Disease

Marotta, G., Basagni, F., Rosini, M., & Minarini, A. (2020) · Molecules · doi:10.3390/molecules25174005 · Cited by 61 · see citing works

Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects <i>In Vitro</i> and Neuroprotective Effects in a Pharmacological Alzheimer’s Disease Mouse Model

He, F., Chou, C. J., Scheiner, M., Poeta, E., Yuan Chen, N., Gunesch, S., Hoffmann, M., Sotriffer, C., Monti, B., Maurice, T., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01940 · Cited by 66 · see citing works

Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer’s Treatment: Systematic Review

ALNasser, M. N., Alboraiy, G. M., Alsowig, E. M., & Alqattan, F. M. (2025) · Brain Sciences · doi:10.3390/brainsci15020215 · Cited by 35 · see citing works

On the electrofluorination of derivatives of morpholine and piperidine

Meinert, H., Fackler, R., Mader, J., et al. (1989) · Journal of Fluorine Chemistry · doi:10.1016/s0022-1139(00)84465-6 · Cited by 1 · see citing works

Syntheses of 1, 1-Disubstituted-3-aminoguanidines

Toku, H., WATONABE, I., NAKADA, S., et al. (1970) · Journal of Synthetic Organic Chemistry Japan · doi:10.5059/yukigoseikyokaishi.28.237 · Cited by 1 · see citing works

Nuclear magnetic resonance studies of heterocyclic fluorine compounds. Part 2.—Perfluoro-N-fluoro-piperidine and perfluoro-N-fluoro-morpholine ring systems

Lee, J., & Orrell, K. G. (1967) · Transactions of the Faraday Society · doi:10.1039/tf9676300016 · Cited by 12 · see citing works

Spectroscopic and Kinetic Evidence for an Accumulating Intermediate in an SNV Reaction with Amine Nucleophiles. Reaction of Methyl β-Methylthio-α-nitrocinnamate with Piperidine and Morpholine

Bernasconi, C. F., Brown, S. D., Eventova, I., et al. (2007) · The Journal of Organic Chemistry · doi:10.1021/jo062602s · Cited by 11 · see citing works

Oxidation of some Alicyclic Amines by Potassium Hexacyanoferrate (III) in Alkaline Medium: A Kinetic and Mechanistic Study

Al-Subu, M. M., Amer, A. A., Jondi, W., et al. (2001) · An-Najah University Journal for Research - A (Natural Sciences) · doi:10.35552/anujr.a.15.1.673 · Cited by 1 · see citing works